{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:40:27Z","timestamp":1753180827597},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,19]]},"abstract":"Abstract<\/jats:title>Purpose<\/jats:title>The increase in vasopressin price has required many healthcare systems to consider cost-saving strategies. To combat rising medication costs, our institution changed formulations from 50 units\/250 mL to 20 units\/100 mL and removed vasopressin from automated dispensing cabinets (ADCs).<\/jats:p><\/jats:sec>Methods<\/jats:title>This retrospective review occurred at a 545-bed academic medical center with 97 adult intensive care unit beds. Adult patients receiving a continuous vasopressin infusion were included with no exclusion criteria. A 1-month period was assessed before and after changing the formulation (pre and post groups, respectively). Duplicate bags compounded by pharmacy and bedside teams were also assessed in the pre group. The primary outcome was the estimated annual cost savings due to formulation change with a secondary outcome of estimated annual cost savings due to removal of vasopressin from ADCs. Each 20-unit vial of vasopressin cost $183.21 (wholesale acquisition cost) at the time of the study.<\/jats:p><\/jats:sec>Results<\/jats:title>In the pre group, 39 patients requiring a vasopressin infusion were allocated an average of 2 bags each costing $1,099.26 per patient. In the post group, 41 patients required an average of 4 bags each costing $732.84 per patient. With respect to the primary outcome, a savings of $366.42 per patient and an average of 40 patients per month would lead to an annual cost savings of $175,881.60. Secondary outcome analysis identified 9 duplicate bags prepared in the pre group; therefore, removal of vasopressin from ADCs is estimated to provide additional cost savings of $59,360.04. The estimated annual cost savings from both initiatives is $235,241.64.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Changing the vasopressin formulation and removing it from ADCs resulted in a significant cost savings to the health system.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxac142","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T19:08:13Z","timestamp":1653332893000},"page":"S74-S78","source":"Crossref","is-referenced-by-count":2,"title":["Adjusting vasopressin availability and formulation: A cost-savings initiative"],"prefix":"10.1093","volume":"79","author":[{"given":"Summer","family":"Sizemore","sequence":"first","affiliation":[{"name":"Emory Healthcare , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan Van Berkel","family":"Patel","sequence":"additional","affiliation":[{"name":"Emory Healthcare , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breanna","family":"Carter","sequence":"additional","affiliation":[{"name":"Emory Healthcare , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Garrett","sequence":"additional","affiliation":[{"name":"Emory Healthcare , Atlanta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"2022081908573458500_CIT0001","volume-title":"Package insert. Par Pharmaceutical","author":"Vasostrict (vasopressin)","year":"2020"},{"key":"2022081908573458500_CIT0002","volume-title":"Lexi-Drugs [proprietary data]","author":"Vasopressin","year":"2021"},{"issue":"3","key":"2022081908573458500_CIT0003","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"issue":"11","key":"2022081908573458500_CIT0004","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"3","key":"2022081908573458500_CIT0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jac5.1079","article-title":"Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies","volume":"2","author":"Hammond","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"issue":"4","key":"2022081908573458500_CIT0006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/CCM.0000000000005305","article-title":"Association between vasopressin rebranding and utilization in patients with septic shock","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit Care Med"},{"issue":"13","key":"2022081908573458500_CIT0007","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ajhp\/zxab153","article-title":"A single-center cost analysis assessing a change in vasopressin formulation","volume":"78","author":"Kelly","year":"2021","journal-title":"Am J Health-Syst Pharm"},{"issue":"24","key":"2022081908573458500_CIT0008","first-page":"e881","article-title":"2019 American Heart Association focused update on advanced cardiovascular life support: use of advanced airways, vasopressors, and extracorporeal cardiopulmonary resuscitation during cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care","volume":"140","author":"Panchal","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"2022081908573458500_CIT0009","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5492\/wjccm.v9.i5.88","article-title":"Vasopressin in vasoplegic shock: a systematic review","volume":"9","author":"Webb","year":"2020","journal-title":"World J Crit Care Med"},{"key":"2022081908573458500_CIT0010","author":"American Society of Health-System Pharmacists"},{"key":"2022081908573458500_CIT0011","volume-title":"USP general chapter <797> pharmaceutical compounding\u2014sterile preparations","author":"United"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac142\/43993179\/zxac142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/Supplement_3\/S74\/45472930\/zxac142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/Supplement_3\/S74\/45472930\/zxac142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:54:30Z","timestamp":1700621670000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/Supplement_3\/S74\/6590869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":11,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac142","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,5,23]]}}}